Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer

Wei Zhang; Zhifen Zhang

doi:10.18632/oncotarget.13361

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer

Wei Zhang _ and Zhifen Zhang

PDF | HTML | How to cite

Oncotarget. 2016; 7:86621-86629. https://doi.org/10.18632/oncotarget.13361

Metrics: PDF 1655 views | HTML 1908 views | ?

Abstract

Wei Zhang1, Zhifen Zhang1

1Department of Gynecology, Nanjing Medical University, Affiliated Hangzhou Hospital, Hangzhou First People’s Hospital, 310006, Hangzhou, China

Correspondence to:

Zhifen Zhang, email: [email protected]

Keywords: ERCC2, XRCC2, ovarian cancer, meta-analysis, single nucleotide polymorphism

Received: October 07, 2016 Accepted: October 29, 2016 Published: November 15, 2016

ABSTRACT

Recent studies explored XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer (OC) risk. However, the association between these two single nucleotide polymorphisms and OC risk remains conflicting. Thus, we conducted a comprehensive systematic review and meta-analysis to investigate the association. We searched the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. 15 case-control studies published in 11 papers including 4,757 cases and 8,431 controls were included in this meta-analysis. No associations were obtained between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and OC risk. Stratification analyses of Hardy–Weinberg equilibrium status indicated that rs3218536 polymorphism was associated with the decreased risk of OC when in analysis of combined HWE positive studies. In conclusion, this meta-analysis indicates that XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms may not be associated with the risk of OC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13361

Publication Alerts

Research Papers:

Associations between XRCC2 rs3218536 and ERCC2 rs13181 polymorphisms and ovarian cancer

Abstract